



US006010912A

United States Patent [19]

[11] **Patent Number:** **6,010,912**

Davies

[45] **Date of Patent:** **Jan. 4, 2000**

[54] **ANTENATAL SCREENING FOR CHROMOSOMAL ABNORMALITIES**

[75] Inventor: **Christopher John Davies**, Caerphilly, United Kingdom

[73] Assignee: **Johnson & Johnson Clinical Diagnostics, Inc.**, Rochester, N.Y.

[21] Appl. No.: **08/566,467**

[22] Filed: **Dec. 4, 1995**

Related U.S. Application Data

[63] Continuation of application No. 08/256,320, filed as application No. PCT/EP93/03296, Nov. 24, 1993, abandoned.

[30] **Foreign Application Priority Data**

Nov. 28, 1992 [GB] United Kingdom 9224965

[51] **Int. Cl.⁷** **G01N 33/68**

[52] **U.S. Cl.** **436/510**; 436/65; 436/86; 436/87; 436/811; 436/817; 436/818; 705/2

[58] **Field of Search** 436/65, 86, 87, 436/131, 510, 518, 811, 817, 818; 364/413.09; 705/2

[56] **References Cited**

U.S. PATENT DOCUMENTS

4,874,693	10/1989	Bogart	435/7
5,100,806	3/1992	Macri	436/518
5,252,489	10/1993	Macri	436/87
5,258,907	11/1993	Macri	364/413
5,840,586	11/1998	Davies	436/510

FOREIGN PATENT DOCUMENTS

327337	4/1990	European Pat. Off. .
362294	4/1990	European Pat. Off. .
90/08325	7/1990	WIPO .

OTHER PUBLICATIONS

Wald et al., Brit. J. Obst. & Gyn., 95, 334-341, 1988.
Wald et al., Brit.Med. J., 297, 883-887, 1988.
Reynolds et al., Ann. Clin. Biochem., 27, 452-458, 1989.
Kratzer et al., Am.J. Hum. Genet., 51, (4 (4 Suppl.)), 1992, P. A268, Abstract 1057.
Tim Reynolds and Rhys John: "Comparison of Assay Kits for Unconjugated Estriol Show That Expressing Results as Multiples of the Median Causes Unacceptable Variation in Calculated Risk Factors for Down Syndrome", Clin. Chem. 38:9, pp. 1888-1893, 1992.
Tim Reynolds et al.: "Utility of Unconjugated Estriol in Screening for Down Syndrome is Not Proven", Clin. Chem., 39:9, pp. 2023-2025, 1993.
H.S. Cuckle, Clinical Chemistry, 38, 1687-1689, 1992.
Stabile et al, Prenatal Diagnosis, 8, 387-391, 1988.

Primary Examiner—David Saunders

[57] **ABSTRACT**

A method for antenatal screening for chromosomal abnormalities in which maternal blood from a pregnant woman is measured for levels of free beta hCG and at least a second serum marker and/or precursors and metabolites of these markers and the measured levels of these markers together with the gestational age of the pregnant woman are compared to reference values at various gestational ages of the levels for free beta hCG and the second serum marker in (a) pregnant women carrying foetuses having the abnormalitie (s) subject to the screen and (b) pregnant women carrying normal foetuses, the comparison being indicative of the risk of the pregnant woman carrying a foetus with an abnormality subject to the screen characterised in that the second serum marker is pregnancy associated plasma protein A (PAPPA) and the screen is carried out by the end of the thirteenth (13th) completed week of pregnancy.

4 Claims, 3 Drawing Sheets